- 【Updated on January 20, 2026】 Integration of CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on November 26, 2025】Regarding the recording of “Research Data” and “Evidence Data”
- CiNii Research researchers search function has been released.
Impact of Age on Prescribing Patterns of Cardiovascular Medications in Older Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease: A Cross-Sectional Study
-
- Tanaka Shigeru
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
-
- Kitamura Hiromasa
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
-
- Tsuruya Kazuhiko
- Department of Nephrology, Nara Medical University
-
- Kitazono Takanari
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
-
- Nakano Toshiaki
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Search this article
Description
<p> Aim: Older patients with chronic kidney disease (CKD) are more likely to be excluded from clinical trials. This exclusion affects the quality of cardiovascular disease (CVD) prevention in this population.</p><p>Methods: Baseline data from the Fukuoka Kidney Disease Registry (FKR) cohort, which included 4476 adult patients with CKD stages G1–G5, were cross-sectionally analyzed to compare the use of recommended drugs for preventing CVD in each age group.</p><p>Results: Different prescribing patterns were observed according to age for the cardiovascular drug classes. Older patients with CKD were less likely to receive renin–angiotensin system (RAS) inhibitors and were more likely to receive calcium channel blockers. The proportion of anticoagulation prescriptions for patients with CKD and atrial fibrillation decreased in the older age group (≥ 75 years). However, the proportion of antiplatelet therapy in patients with ischemic CVD increased linearly with age, even in the very old group aged ≥ 85 years. These findings suggest a severe cardiovascular burden in patients with CKD. Notably, RAS inhibitor use was avoided in the older group despite a severe cardiovascular burden, such as a high prevalence of CVD history and massive albuminuria ＞300 mg/g creatinine. This finding indicates that an older age independently contributed to the non-use of RAS inhibitors, even after adjusting for other covariates.</p><p>Conclusions: This study suggests that age is a potential barrier to the treatment of patients with CKD and highlights the need to establish individualized treatment strategies for cardiovascular protection in this population.</p>
Journal
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 31 (10), 1427-1442, 2024-10-01
Japan Atherosclerosis Society